Ranked #6,128 of 8,699 institutional investors
NEXTBio Capital Management LP
Austin, TX
$206M
US stock portfolio at live prices · today +$350K (+0.17%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $234M
- Change from Q2 2026
- +$17.0M (+7.81%)
- Positions
- 22 · 4 new, 2 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$25.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPTGX 13.2%STTK 8.25%RYTM 7.49%CMPS 7.47%PVLA 5.70%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. | 219,333 | $27.2M | 13.2% | Unchanged |
| STTK Shattuck Labs, Inc. | 3,727,348 | $17.0M | 8.25% | Unchanged |
| RYTM Rhythm Pharmaceuticals, Inc. | 131,758 | $15.4M | 7.49% | Unchanged |
| CMPS COMPASS Pathways plc | 1,775,759 | $15.4M | 7.47% | Unchanged |
| PVLA Palvella Therapeutics, Inc. | 80,409 | $11.7M | 5.70% | Reduced −11% |
| XENE Xenon Pharmaceuticals Inc. | 310,225 | $11.7M | 5.67% | Added +69% |
| VOR Vor Biopharma Inc. | 620,931 | $11.5M | 5.59% | Reduced −30% |
| ZBIO Zenas BioPharma, Inc. | 426,736 | $10.7M | 5.20% | Unchanged |
| PCVX Vaxcyte, Inc. | 107,223 | $6.3M | 3.04% | Unchanged |
| VSTM Verastem, Inc. | 906,742 | $6.2M | 3.03% | Reduced −31% |
| KRSA Korsana Biosciences, Inc. | 175,403 | $6.2M | 3.03% | New |
| IVA Inventiva S.A. | 1,787,984 | $6.2M | 3.00% | Unchanged |
| GPCR Structure Therapeutics Inc. | 312,496 | $5.3M | 2.60% | Unchanged |
| ORIC ORIC Pharmaceuticals, Inc. | 684,476 | $5.3M | 2.56% | Reduced −3% |
| ZLAB Zai Lab Limited | 238,362 | $5.2M | 2.54% | Added +30% |
| COGT Cogent Biosciences, Inc. | 178,036 | $4.9M | 2.40% | Added +36% |
| IRON Disc Medicine, Inc. | 52,655 | $4.0M | 1.95% | Unchanged |
| BLSM BlossomHill Therapeutics, Inc. | 250,000 | $3.6M | 1.75% | New |
| LBRX LB Pharmaceuticals Inc | 69,549 | $2.8M | 1.35% | Added +2% |
| ADRX ADARx Pharmaceuticals, Inc. | 100,000 | $1.4M | 0.69% | New |
| GLUE Monte Rosa Therapeutics, Inc. | 111,455 | $993K | 0.48% | New |
| EVMN Evommune Inc | 119,063 | $862K | 0.42% | Unchanged |